News|Videos|March 6, 2025
The Evolving Landscape of mBC Treatment: Unmet Needs and Future Predictions
Author(s)Joyce O’Shaughnessy, MD, Alison Conlin, MD
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. Conlin to Dr. O’Shaughnessy: Looking ahead, how do you see the treatment landscape evolving?
- What impact might the SERENA-6 trial have on sequencing practices (
Turner et al. Future Oncology 2023 )? - What mechanisms of resistance to PI3K/AKT pathway inhibitors or oral SERDs do you anticipate?
- What unmet needs remain to be addressed?
- What impact might the SERENA-6 trial have on sequencing practices (
Advertisement
Related to this article
Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.
Adding pembrolizumab to adjuvant radiation did not meet prespecified superiority criteria in patients with stage I/II high-intermediate–risk dMMR endometrioid endometrial cancer in the phase 3 NRG-GY020 trial.
Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.
Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.
Adding darolutamide to androgen deprivation and primary or salvage radiation lowered metastasis risk in very high-risk localized prostate cancer.
INCA33890 combined with standard-of-care therapy produced responses in first- and third-line metastatic microsatellite stable colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
2
DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC
3
Adjuvant Intismeran Autogene Plus Pembrolizumab Improves RFS and DMFS in Melanoma
4
DASL-HiCaP: Darolutamide Plus ADT and Radiation Therapy Improves MFS in Very High-Risk Localized Prostate Cancer
5